Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07441642

RecruitingPhase 2

Sponsor: Novartis Pharmaceuticals

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions: FWY003, Placebo

Countries: United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Eligibility overview

Sex: ALL

Age: 50 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

Male or female participants ≥ 50 years of age.

* A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye.

  1. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), respectively)
  2. If GA lesion is multifocal, then the total lesion area must be between 2.5-17.5 mm2 and at least one lesion should have an area of at least 1.25 mm2
  3. Entire GA lesion must be visualized on the macula centered image and not contiguous with peripapillary atrophy
* ETDRS BCVA ≥ 35 letters (20/200) in the study eye.

Exclusion Criteria:

* A history of, or current evidence of, choroidal neovascularization (exudative MNV) in either eye, as determined by the central reading center on multimodal imaging at screening.
* Previous cell or gene therapy in either eye.
* Macular atrophy in either eye due to a cause other than AMD, such as Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.
* Intraocular surgery, including cataract and vitreoretinal surgery, in the study eye within 3 months prior to Baseline.
* Presence of significant media opacity, eye movement disorder (nystagmus), severe ptosis, extraocular motility restriction or head tremor, which in the opinion of the investigator, would prevent adequate fundus visualization or interfere with retinal imaging data quality.

Other protocol-defined inclusion/exclusion criteria may apply.
Locations (51)
  • Huntington Beach, California, United States
  • Sacramento, California, United States
  • Santa Barbara, California, United States
  • Boynton Beach, Florida, United States
  • Deerfield Beach, Florida, United States
  • St. Petersburg, Florida, United States
  • Boston, Massachusetts, United States
  • Toms River, New Jersey, United States
  • New York, New York, United States
  • New York, New York, United States
  • Erie, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Bellaire, Texas, United States
  • Houston, Texas, United States
  • Katy, Texas, United States
  • Albury, New South Wales, Australia
  • Parramatta, New South Wales, Australia
  • Strathfield, New South Wales, Australia
  • East Melbourne, Victoria, Australia
  • Sofia, Bulgaria
  • London, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Prague, Czechia
  • Prague, Czechia
  • Lyon, Rhone, France
  • Créteil, France
  • Dijon, France
  • Paris, France
  • Bonn, Germany
  • Ludwigshafen, Germany
  • + 21 more on CT.gov